Zymeworks Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands) (unaudited)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $84,519 | $(39,921) |
| Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | ||
| Depreciation of property and equipment | 2,861 | 2,771 |
| Amortization of intangible assets | 1,128 | 3,871 |
| Stock-based compensation expense | 41,352 | 19,184 |
| Amortization of operating lease right-of-use assets | 3,349 | 2,461 |
| Amortization of debt issuance costs | 262 | — |
| Non-cash royalty revenue related to sale of future revenue | (990) | — |
| Non-cash interest expense related to sale of future revenue | 15,083 | — |
| Deferred income tax recovery | (3,509) | (465) |
| Unrealized foreign exchange (gain) loss | (554) | 227 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (292,198) | 26,487 |
| Prepaid expenses and other current assets | 4,087 | 11,629 |
| Accounts payable and accrued liabilities | 43,698 | (24,983) |
| Operating lease liabilities | (2,609) | (2,504) |
| Deferred revenue | (365) | (22,391) |
| Income taxes payable | 2,181 | 888 |
| Net cash (used in) provided by operating activities | (101,705) | (22,746) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (62,532) | (139,233) |
| Proceeds from marketable securities | 292,103 | 162,160 |
| Acquisition of property and equipment | (289) | (940) |
| Acquisition of business, net of cash acquired | (532,020) | — |
| Acquisition of intangible assets | — | (692) |
| Net cash (used in) provided by investing activities | (302,738) | 21,295 |
| Cash flows from financing activities: | ||
| Issuance of common stock on exercise of stock options | 14,340 | 10,079 |
| Issuance of common stock through employee stock purchase plan | 751 | 1,425 |
| Purchases of common stock for retirement | (140,092) | (16,216) |
| Private placement for issuance of common stock | — | 4,988 |
| Proceeds from sale of future revenue | 596,500 | — |
| Payments for transaction costs related to sale of future revenue | (7,882) | — |
| Deferred financing fees | — | (93) |
| Net cash provided by financing activities | 463,617 | 183 |
| Effect of exchange rate changes on cash and cash equivalents | 133 | (1) |
| Net change in cash and cash equivalents | 59,307 | (1,269) |
| Cash and cash equivalents, beginning of period | 41,157 | 66,103 |
| Cash and cash equivalents, end of period | $100,464 | $64,834 |
| Supplemental cash flow information: | ||
| Net cash paid during the period for income taxes | $1,559 | $1,243 |
| Supplemental disclosure of non-cash investing and financing items: | ||
| Consideration payable for Theravance Merger | $28,393 | $— |
| Issuance of common stock upon exercise of pre-funded warrants | — | 49,862 |
| Leased assets obtained in exchange for operating lease liabilities | — | 2,443 |
| Debt issuance costs related to sale of future royalties not yet paid | 5,825 | — |
| Acquisition of property and equipment and intangible assets not yet paid | 168 | — |
| Purchases of common stock not settled | — | 504 |
The accompanying notes are an integral part of these financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.